Literature DB >> 21691209

Prediction of esophageal varices in hepatic cirrhosis by noninvasive markers.

Jean Rodrigo Tafarel1, Luciano Henrique Lenz Tolentino, Lucianna Motta Correa, Danielle Rossana Bonilha, Patrícia Piauilino, Fernanda Prata Martins, Rodrigo Azevedo Rodrigues, Frank Shigeo Nakao, Ermelindo Della Libera, Angelo Paulo Ferrari, Maria Rachel da Silveira Röhr.   

Abstract

OBJECTIVE: To determine whether Model for End-stage Liver Disease (MELD) Child-Turcotte-Pugh (CTP) classification, AST to platelet ratio index (APRI), and laboratory tests could predict the presence of esophageal varices (EV) or varices which need prophylactic therapy (medium or large size EV).
METHODS: Three hundred patients with cirrhosis (193 men; mean age 53.1 years; majority with chronic C hepatitis) were prospectively analyzed. The presence of EV (any size and medium or large EV) was correlated with patients' characteristics (MELD, CTP classification, APRI, platelets count, and liver tests).
RESULTS: One hundred and seventy-one patients (57%) had EV, of whom 35% (105) had varices which need prophylactic therapy (VPT). The distribution of EV according to CTP classification was as follows: A, 49%; B, 75.3% and C, 80%. Independent predictors of EV were: MELD higher than 8 (P=0.02); APRI higher than 1.64 (P=0.01); platelet count lower than 93,000/mm³ (P<0.01); aspartate aminotransferase higher than 1.34 × UNL (P=0.01), and total bilirubin higher than 1 mg/dl (P=0.04). MELD higher than 8 had the highest discriminative value for presence of EV (sensitivity=80.1%; specificity=51.2%; area under receiver operating characteristics=0.68). Factors independently associated with VPT were: thrombocytopenia (<92,000/mm³; P<0.01) and aspartate aminotransferase higher than 1.47 × UNL (P=0.03). Platelet count lower than 92,000/mm³ had sensitivity of 65.7%, specificity of 57.9%, and an area under receiver operating characteristics of 0.62 for the presence of VPT.
CONCLUSION: High values on MELD are associated with EV and thrombocytopenia, with varices which need prophylactic therapy. As a result of their low sensitivity and specificity, it is suggested to maintain the recommendation of upper gastrointestinal endoscopy for all patients with cirhosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691209     DOI: 10.1097/MEG.0b013e3283488a88

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  14 in total

Review 1.  Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis.

Authors:  Agostino Colli; Juan Cristóbal Gana; Jason Yap; Thomasin Adams-Webber; Natalie Rashkovan; Simon C Ling; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2017-04-26

2.  Non-invasive Diagnosis of Oesophageal Varices Using Systemic Haemodynamic Measurements by Finometry: Comparison with Other Non-invasive Predictive Scores.

Authors:  Kara Rye; Gerri Mortimore; Andrew Austin; Jan Freeman
Journal:  J Clin Exp Hepatol       Date:  2016-05-13

3.  Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis.

Authors:  Parastoo Jangouk; Laura Turco; Ana De Oliveira; Filippo Schepis; Erica Villa; Guadalupe Garcia-Tsao
Journal:  Liver Int       Date:  2017-03-07       Impact factor: 5.828

4.  Soluble CD163 for Prediction of High-Risk Esophageal Varices and Variceal Hemorrhage in Patients with Liver Cirrhosis.

Authors:  Mohamed Yousri Taher; Abeer El-Hadidi; Assem El-Shendidi; Ahmed Sedky
Journal:  GE Port J Gastroenterol       Date:  2021-07-27

5.  Noninvasive methods for prediction of esophageal varices in pediatric patients with portal hypertension.

Authors:  Marina Rossato Adami; Cristina Targa Ferreira; Carlos Oscar Kieling; Vania Hirakata; Sandra Maria Gonçalves Vieira
Journal:  World J Gastroenterol       Date:  2013-04-07       Impact factor: 5.742

6.  Facility- and Patient-Level Factors Associated with Esophageal Variceal Screening in the USA.

Authors:  Jennifer A Flemming; Varun Saxena; Hui Shen; Norah A Terrault; Catherine Rongey
Journal:  Dig Dis Sci       Date:  2015-09-12       Impact factor: 3.199

7.  Immature platelet fraction and thrombopoietin in patients with liver cirrhosis: A cohort study.

Authors:  Philip Rauber; Frank Lammert; Katharina Grotemeyer; Beate Appenrodt
Journal:  PLoS One       Date:  2018-02-13       Impact factor: 3.240

8.  Correlation of platelets count with endoscopic findings in a cohort of Egyptian patients with liver cirrhosis.

Authors:  Sherief Abd-Elsalam; Eslam Habba; Walaa Elkhalawany; Salwa Tawfeek; Hassan Elbatea; Ferial El-Kalla; Hanan Soliman; Samah Soliman; Mohamed Yousef; Abdelrahman Kobtan; Sally El Nawasany; Sheren Awny; Ibrahim Amer; Loai Mansour; Fatma Rizk
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

9.  Predictors of esophageal varices and first variceal bleeding in liver cirrhosis patients.

Authors:  Bledar Kraja; Iris Mone; Ilir Akshija; Adea Koçollari; Skerdi Prifti; Genc Burazeri
Journal:  World J Gastroenterol       Date:  2017-07-14       Impact factor: 5.742

Review 10.  Diagnostic Accuracy of APRI, AAR, FIB-4, FI, King, Lok, Forns, and FibroIndex Scores in Predicting the Presence of Esophageal Varices in Liver Cirrhosis: A Systematic Review and Meta-Analysis.

Authors:  Han Deng; Xingshun Qi; Xiaozhong Guo
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.